June 2022 Issue | Blood Cancers Today

June 2022

This issue of Blood Cancers Today features a debate on the usefulness of variant allele frequency as a prognostic biomarker for MPNs, a focus on treatment options for BPDCN, and more.

Viewpoints

Editor's Message

Making Medical Strides, Despite Socioeconomic and Cultural Setbacks

Features

News

In the Literature

TP53 Mutation Defines a Unique Subgroup Within MDS/AML with Complex Karyotype

Should TP53-Mutated AML and MDS-EB Be Considered a Single Disease Entity?

Bone Marrow Clonal Hematopoiesis Prevalent in Elderly Patients with BPDCN

Survey Observes 76% Global Increase in Stem Cell Transplants

Meeting News

First-in-Class Dual PIM/FLT3 Kinase Inhibitor SEL24/MEN1703 Demonstrates Single-Agent Activity in AML

DREAMM-4 Combines Belantamab Mafodotin Plus Pembrolizumab for Patients with MM

CAR-T Brexucabtagene Autoleucel Induces Long-Term Response in Patients with MCL

Regulatory Actions

EMA Recommends Conditional Approval of Mosunetuzumab for Follicular Lymphoma

FDA Clears IND Application for Humanized Gamma-Delta Bispecific Antibody

FDA, Finnish Medicines Agency Approve Initiation of Phase I/II Study of Bexmarilimab

Tisagenlecleucel Approved in Europe for Follicular Lymphoma

HM43239 Granted Fast Track Designation for AML

State of the Art

How to Optimize Transplant-Related Care for ALL

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer